- Home
- PNNT vs PRTA Comparison
PNNT vs PRTA Comparison
Compare PNNT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNNT
- PRTA
- Stock Information
- Founded
- PNNT 2007
- PRTA 2012
- Country
- PNNT United States
- PRTA Ireland
- Employees
- PNNT N/A
- PRTA N/A
- Industry
- PNNT Finance: Consumer Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- PNNT Finance
- PRTA Health Care
- Exchange
- PNNT Nasdaq
- PRTA Nasdaq
- Market Cap
- PNNT 423.8M
- PRTA 472.1M
- IPO Year
- PNNT 2007
- PRTA N/A
- Fundamental
- Price
- PNNT $6.53
- PRTA $10.75
- Analyst Decision
- PNNT Sell
- PRTA Buy
- Analyst Count
- PNNT 5
- PRTA 9
- Target Price
- PNNT $6.38
- PRTA $16.14
- AVG Volume (30 Days)
- PNNT 463.2K
- PRTA 584.3K
- Earning Date
- PNNT 11-24-2025
- PRTA 11-06-2025
- Dividend Yield
- PNNT 14.86%
- PRTA N/A
- EPS Growth
- PNNT 21.65
- PRTA N/A
- EPS
- PNNT 0.80
- PRTA N/A
- Revenue
- PNNT $130,923,000.00
- PRTA $10,341,000.00
- Revenue This Year
- PNNT N/A
- PRTA N/A
- Revenue Next Year
- PNNT N/A
- PRTA $602.32
- P/E Ratio
- PNNT $8.19
- PRTA N/A
- Revenue Growth
- PNNT N/A
- PRTA N/A
- 52 Week Low
- PNNT $5.72
- PRTA $4.32
- 52 Week High
- PNNT $7.53
- PRTA $18.78
- Technical
- Relative Strength Index (RSI)
- PNNT 46.36
- PRTA 63.31
- Support Level
- PNNT $6.43
- PRTA $10.34
- Resistance Level
- PNNT $6.53
- PRTA $10.82
- Average True Range (ATR)
- PNNT 0.12
- PRTA 0.54
- MACD
- PNNT 0.02
- PRTA -0.02
- Stochastic Oscillator
- PNNT 57.56
- PRTA 54.81
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.